Andrew Burch | Source | Executive Vice President of Nucleic Acid Products at Trilink Biotechnologies

AB

Andrew Burch

Executive Vice President of Nucleic Acid Products at Trilink Biotechnologies
On the record
Represented by:
Share profile 
Link:
Bio
Edit

Drew Burch is the executive vice president of nucleic acid products at TriLink Biotechnologies.

Drew leads the Nucleic Acid Products team at TriLink Biotechnologies, part of Maravai LifeSciences, helping to enable the development of nucleic acid therapeutics, diagnostics and vaccines. TriLink’s proprietary CleanCap® reagent has been pivotal in many mRNA technologies used around the world for the development and commercialization of vaccine and therapeutic programs, including COVID-19 mRNA vaccines.

Previously, Drew led various businesses for Thermo Fisher Scientific, including as President of its Patheon Softgels CDMO business and European Drug Product CDMO division, as President of its Enterprise Services Division, as leader of it's Licensing and Commercial Supply business, and as VP of Strategy and Business Development for its Life Sciences Solutions group.

Over his 9-year tenure at Thermo Fisher Scientific, Drew supported the development of the first CAR-T therapies in collaboration with Novartis and Juno as well as the first universal next-generation sequencing (NGS) companion diagnostic with Novartis and Pfizer. Drew helped launch numerous partnerships for sequencing and diagnostics, helped supported the execution of several acquisitions, launched an mRNA supply initiative, and digitized the Thermo Fisher Scientific CDMO and instrumentation businesses.

Drew started his career as an advisor to healthcare companies on mergers and acquisitions. Over a two decade period, he built and led teams advising executives and boards of many of the world's leading pharmaceutical, biotechnology, life sciences tools, diagnostics, managed care and hospital companies. After rising to managing director at Merrill Lynch, he built global healthcare M&A advisory teams for Lehman Brothers and Barclays. Barclays achieved 2013 rank of #3 in U.S. healthcare M&A and #4 in global healthcare M&A.

Employment
Sign up to view all
Media
Sign up to view all
Recent Quotes
Sign up to view all

  • "Prior to the pandemic, there had been a trend in the pharma industry towards a lean, just-in-time supply chain – much less effective in an emergency. Just-in-time inventory is perfect when everything is business as usual. However, in pandemic preparedness, you must plan for the unplanned and extend flexibility. For example, many companies now stockpile certain raw materials to provide flexibility. Since mRNA offers the opportunity to develop a new vaccine faster and uses a common set of raw materials regardless of the vaccine target, it can be a particularly valuable approach.”

Headshots